IQVIA (NYSE:IQV) Price Target Cut to $235.00

IQVIA (NYSE:IQV) had its price objective cut by stock analysts at Robert W. Baird from $241.00 to $235.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical research company’s stock. Robert W. Baird’s target price would suggest a potential upside of 7.09% from the company’s current price.

Other equities research analysts also recently issued research reports about the stock. Barclays decreased their price target on shares of IQVIA from $275.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, June 28th. Evercore ISI dropped their price target on IQVIA from $250.00 to $230.00 and set an “outperform” rating for the company in a research report on Tuesday. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Sunday, July 7th. Truist Financial cut their target price on IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a research report on Friday, May 3rd. Finally, The Goldman Sachs Group initiated coverage on IQVIA in a research report on Thursday, June 6th. They issued a “buy” rating and a $270.00 price target for the company. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $255.73.

IQVIA Stock Up 3.5 %

Shares of IQV stock opened at $219.44 on Wednesday. The stock has a market cap of $39.98 billion, a P/E ratio of 29.98, a PEG ratio of 1.90 and a beta of 1.49. The company’s fifty day simple moving average is $219.70 and its two-hundred day simple moving average is $229.03. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. IQVIA has a 52 week low of $167.42 and a 52 week high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.11. The company had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. Analysts predict that IQVIA will post 10.11 EPS for the current fiscal year.

Institutional Trading of IQVIA

A number of large investors have recently modified their holdings of the company. CX Institutional lifted its holdings in shares of IQVIA by 5.1% in the 2nd quarter. CX Institutional now owns 1,533 shares of the medical research company’s stock worth $324,000 after buying an additional 75 shares during the period. Fortitude Family Office LLC lifted its stake in IQVIA by 3.7% in the second quarter. Fortitude Family Office LLC now owns 1,921 shares of the medical research company’s stock worth $406,000 after acquiring an additional 68 shares during the period. Gulf International Bank UK Ltd grew its holdings in IQVIA by 1.0% during the 2nd quarter. Gulf International Bank UK Ltd now owns 20,221 shares of the medical research company’s stock worth $4,275,000 after acquiring an additional 194 shares in the last quarter. CWM LLC raised its holdings in shares of IQVIA by 21.2% in the 2nd quarter. CWM LLC now owns 6,640 shares of the medical research company’s stock valued at $1,404,000 after purchasing an additional 1,163 shares in the last quarter. Finally, Mather Group LLC. lifted its position in shares of IQVIA by 11.6% in the 2nd quarter. Mather Group LLC. now owns 596 shares of the medical research company’s stock worth $126,000 after purchasing an additional 62 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.